SRX.AX - Sirtex Medical Limited

ASX - ASX Delayed Price. Currency in AUD
27.77
+0.02 (+0.07%)
At close: 4:11PM AEST
Stock chart is not supported by your current browser
Previous Close27.75
Open27.76
Bid27.77 x 0
Ask27.78 x 0
Day's Range27.76 - 27.85
52 Week Range10.45 - 27.88
Volume285,763
Avg. Volume579,699
Market Cap1.549B
Beta0.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.30 (1.08%)
Ex-Dividend Date2017-09-26
1y Target EstN/A
  • Reuters3 months ago

    Varian Medical swoops on Australia's Sirtex as medical M&A soars

    U.S. cancer-treatment company Varian Medical Systems agreed on Tuesday to buy Australian liver-cancer treatment maker Sirtex Medical for $1.3 billion, the latest in a wave of big M&A deals sweeping the global healthcare sector. Sirtex, whose shares have halved over the past two years, and which swung to a full-year loss after its technology failed in three major tests, recommended the buyout as an "attractive outcome". California-based Varian's offer of A$28 in cash per share is 49 percent above Sirtex's closing price of A$18.83 on Monday, and comes amid a multibillion dollar shopping spree in the sector as big companies buy their way to growth.

  • Sirtex Medical Ltd. breached its 50 day moving average in a Bearish Manner : SRX-AU : October 30, 2017
    Capital Cube6 months ago

    Sirtex Medical Ltd. breached its 50 day moving average in a Bearish Manner : SRX-AU : October 30, 2017

    Categories: Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sirtex Medical Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Capital Cube6 months ago

    Sirtex Medical Ltd. – Value Analysis (ASX:SRX) : October 13, 2017

    Categories: Asia Pacific Value Yahoo FinanceClick here to see latest analysis Capitalcube gives Sirtex Medical Ltd. a score of 54. Our analysis is based on comparing Sirtex Medical Ltd. with the following peers – Starpharma Holdings Limited, Clinuvel Pharmaceuticals Limited and Alchemia Limited (SPL-AU, CUV-AU and ACL-AU). Investment Outlook Sirtex Medical Ltd. has a fundamental score of 54 and has ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Sirtex Medical Ltd. : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sirtex Medical Ltd. Here are 5 ETFs with the largest exposure to SRX-AU. Comparing the performance and risk of Sirtex Medical Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sirtex Medical Limited (ASX:SRX): Risks You Need To Consider Before Buying
    Simply Wall St.7 months ago

    Sirtex Medical Limited (ASX:SRX): Risks You Need To Consider Before Buying

    If you are looking to invest in Sirtex Medical Limited’s (ASX:SRX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Capital Cube8 months ago

    ETFs with exposure to Sirtex Medical Ltd. : September 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sirtex Medical Ltd. Here are 5 ETFs with the largest exposure to SRX-AU. Comparing the performance and risk of Sirtex Medical Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sirtex Medical Ltd. breached its 50 day moving average in a Bearish Manner : SRX-AU : August 24, 2017
    Capital Cube8 months ago

    Sirtex Medical Ltd. breached its 50 day moving average in a Bearish Manner : SRX-AU : August 24, 2017

    Categories: Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sirtex Medical Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of SRX.AX earnings conference call or presentation 22-Aug-17 11:15pm GMT

    Full Year 2017 Sirtex Medical Ltd Earnings Call

  • Sirtex Medical Ltd. : SRX-AU: Dividend Analysis : September 28th, 2016 (record date) : By the numbers : August 16, 2017
    Capital Cube8 months ago

    Sirtex Medical Ltd. : SRX-AU: Dividend Analysis : September 28th, 2016 (record date) : By the numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Sirtex Medical Ltd. with the following peers – Starpharma Holdings Limited, Clinuvel Pharmaceuticals Limited and Alchemia Limited (SPL-AU, CUV-AU and ACL-AU). Dividend Quality Overview Dividend quality trend has not been consistent over the last five years. Dividends were paid during each of these years — ... Read more (Read more...)

  • Capital Cube10 months ago

    Sirtex Medical Ltd. – Value Analysis (ASX:SRX) : June 30, 2017

    Categories: Asia Pacific Value Yahoo FinanceClick here to see latest analysis Capitalcube gives Sirtex Medical Ltd. a score of 68. Our analysis is based on comparing Sirtex Medical Ltd. with the following peers – Starpharma Holdings Limited, Clinuvel Pharmaceuticals Limited and Alchemia Limited (SPL-AU, CUV-AU and ACL-AU). Investment Outlook Sirtex Medical Ltd. has a fundamental score of 68 and has ... Read more (Read more...)

  • Australia's Second Worst-Performing Stock May Have a Silver Lining
    Bloomberg11 months ago

    Australia's Second Worst-Performing Stock May Have a Silver Lining

    Sirtex Medical Ltd., Australia’s second-worst performing stock the past year, may have upside even after its tumor-fighting treatment failed in three major studies.